Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Allurion, founded in 2009 and headquartered in Natick, Massachusetts, is a healthcare technology company specializing in weight loss solutions. The company's primary focus is the development of a procedure-less gastric balloon, which is delivered to patients as part of a comprehensive weight-loss experience. Allurion, formerly known as elipses, has raised approximately $79.77 million in funding to date, indicating significant investor interest in their innovative approach to weight management.
As a private company, Allurion has been making strides in the healthcare technology sector with its unique gastric balloon solution. However, there is currently no concrete information available regarding Allurion's plans for an initial public offering (IPO). The company's ticker symbol ALUR is listed on the New York Stock Exchange (NYSE), but it's important to note that this does not necessarily indicate an imminent IPO.
For potential investors interested in Allurion stock or looking to buy Allurion shares, it's crucial to understand that the company remains private at this time. Any discussions about investing in Allurion or the possibility of an Allurion IPO should be approached with caution, as no official announcements have been made.
Given the lack of specific news or reports about Allurion's IPO prospects, we cannot provide any predictions or speculations about the likelihood or timing of such an event. Investors should continue to monitor official company announcements and verified financial news sources for any updates regarding Allurion's future plans, including potential public offerings.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Allurion's IPO prospects remain uncertain, investors eager to gain exposure to innovative healthcare technology companies don't have to wait. At Linqto, we offer members access to interests in promising pre-IPO private companies, including potential leaders in the medical device and weight loss sectors. Our platform allows you to diversify your portfolio with lower minimum investments, potentially benefiting from the growth of emerging healthcare innovators before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
